HareshS.JhangianiMDMBA

Hematology • Fountain Valley, CA

Physician

Join to view full profile

Dr. Jhangiani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Jhangiani's full profile

Already have an account?

Office
11180 Warner Ave
Ste 351
Fountain Valley, CA 92708
Phone+1 714-698-0300

Fax+1 714-698-0303
Is this information wrong?

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 1987 - 1988
Kaiser Permanente Southern California (Los Angeles)Fellowship, Hematology and Medical Oncology, 1985 - 1987
Kaiser Permanente Southern California (Los Angeles)Residency, Internal Medicine, 1983 - 1984
Charles R Drew UniversityResidency, Pediatrics, 1982 - 1983
St Joseph Mercy-OaklandResidency, Internal Medicine, 1981 - 1982
St Joseph Mercy-OaklandInternship, Transitional Year, 1980 - 1981
Topiwala National Medical CollegeClass of 1978

Certifications & Licensure

CA State Medical License 1982 - 2026
MI State Medical License 1982 - 2013
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 1997

Clinical Trials

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Completed
Phase 4
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
Completed
Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Start of enrollment: 2014 Apr 01
Recruiting
Phase 3
Rociletinib (CO-1686) USA Expanded Access Program
No longer available
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors Start of enrollment: 2018 Jan 02
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Jonathan Afari, Tanya M Spektor, Carley Turner, Alexa Cohen, Alberto Bessudo, Haresh Jhangiani, Nashat Gabrail, Samir Kubba, Jeffrey D Neidhart, Shahrooz Eshaghian, Re...> ;Experimental Hematology. 2022 Oct 1
8 citations
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak, Veena Charu, Roger M. Lyons, Jack Aiello, Kimberly Bogard, Renda H. Ferrari, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Nov 1
49 citations
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuz...
Sara A. Hurvitz, Florence Dalenc, Mario Campone, Ruth O'Regan, Vivianne C. G. Tjan-Heijnen, Joseph Gligorov, Antonio Llombart, Haresh Jhangiani, Hamid R. Mirshahidi, E...> ;Breast Cancer Research and Treatment. 2013 Oct 8
120 citations
Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
Eyal Meiri, Haresh S. Jhangiani, James J. Vredenburgh, Luigi M. Barbato, Frederick J. Carter, Hwa-Ming Yang, Vickie Baranowski> ;Current Medical Research and Opinion. 2007 Feb 1
Tolerability of dronabinol alone, ondansetron alone and the combination of dronabinol plus ondansetron in delayed chemotherapy-induced nausea and vomiting.
Jhangiani H, Meiri E, Vredenburgh J, Barbato L, Yang H, Li D, Baranowski V, Tse N> ;J. Clin. Oncol.. 2005-06-01
Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting (CINV).
Meiri E, Jhangiani H, Vredenburgh J, Barbato L, Yang H, Li D, Baranowski V, Tse N> ;J. Clin. Oncol.. 2005-06-01
Join now to see all

Professional Memberships

American College of Physicians - ACP
Fellow
American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Corona Regional Medical CenterCorona, California
Fountain Valley Regional HospitalFountain Valley, California
Hoag Memorial Hospital PresbyterianNewport Beach, California
MemorialCare, Orange Coast Memorial Medical CenterFountain Valley, California
Parkview Community Hospital Medical CenterRiverside, California
Riverside Community HospitalRiverside, California